Radionuclide spatial distribution and dose deposition for in vitro assessments of
212Pb
clonogenic assay
dosimetry
in vitro irradiations
targeted alpha therapy
α-emitters
Journal
Medical physics
ISSN: 2473-4209
Titre abrégé: Med Phys
Pays: United States
ID NLM: 0425746
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
19
06
2019
revised:
14
11
2019
accepted:
09
12
2019
pubmed:
16
12
2019
medline:
30
12
2020
entrez:
16
12
2019
Statut:
ppublish
Résumé
Targeted alpha therapy (TAT) takes advantage of the short-range and high-linear energy transfer of α-particles and is increasingly used, especially for the treatment of metastatic lesions. Nevertheless, dosimetry of α-emitters is challenging for the very same reasons, even for in vitro experiments. Assumptions, such as the uniformity of the distribution of radionuclides in the culture medium, are commonly made, which could have a profound impact on dose calculations. In this study we measured the spatial distribution of α-emitting Two experimental setups were implemented without cells to measure α-particle count rates and energy spectra in culture medium containing 15 kBq of Experimental count rates and energy spectra showed differences in measurements taken at the top and the bottom of dishes and temporal variations that did not follow This study demonstrated that accurate dosimetry of α-emitters requires the experimental determination of radionuclide spatial and temporal distribution and highlighted that in vitro assessment of dose for TAT cannot only rely on a uniform distribution of activity in the culture medium. The reliability and reproducibility of future experiments should benefit from specifically developed dosimetry tools and methods.
Substances chimiques
Immunoconjugates
0
Lead Radioisotopes
0
Lead-212
0
Vascular Cell Adhesion Molecule-1
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1317-1326Subventions
Organisme : Fédération pour la Recherche sur le Cerveau par l'opération Rotary "Espoir en tête »
Organisme : French Ministère de l'Enseignement Supérieur et de la Recherche
Organisme : Medical Research Council
ID : MC_PC_12004
Pays : United Kingdom
Organisme : Engineering and Physical Sciences Research Council
Organisme : Cancer Research UK
ID : 22906
Pays : United Kingdom
Organisme : CNRS
Organisme : European Union-Fonds Européen de Développement Régional
Organisme : Cancer Research UK
ID : C5255/A15935
Pays : United Kingdom
Organisme : CRUK Oxford Centre
Organisme : Oxford Centre for Drug Delivery Devices
ID : EP/L024012/1
Organisme : Conseil Régional-Normandie
Organisme : CEA
Organisme : ANR
ID : ANR-11-LABEX-0018-01
Organisme : CRUK/EPSRC Cancer Imaging Centre Oxford
ID : C5255/A16466
Organisme : ANR
ID : ANR-10-EQPX1401
Organisme : Université de Caen-Normandie
Informations de copyright
© 2019 American Association of Physicists in Medicine.
Références
Sgouros G. Alpha-particles for targeted therapy. Adv Drug Deliv Rev. 2008;60:1402-1406.
Zalutsky MR, Bigner DD. Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates. Acta Oncol. 1996;35:373-379.
Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 1953;312:638-648.
Horsman MR, Overgaard J. The impact of hypoxia and its modification of the outcome of radiotherapy. J Radiat Res. 2016;57:i90-i98.
Guerard F, Barbet J, Chatal J-F, Kraeber-Bodere F, Cherel M, Haddad F. Which radionuclide, carrier molecule and clinical indication for alpha-immunotherapy. Q J Nucl Med Mol Imaging. 2015;59:161-167.
Maffioli L, Florimonte L, Costa DC, et al. New radiopharmaceutical agents for the treatment of castration-resistant prostate cancer. Q J Nucl Med Mol Imaging. 2015;59:420-438.
Barbet J, Bardiès M, Bourgeois M, et al. Radiolabeled antibodies for cancer imaging and therapy. Methods Mol Biol. 2012;907:681-697.
Falzone N, Ackerman NL, Rosales LF, et al. Dosimetric evaluation of radionuclides for VCAM-1-targeted radionuclide therapy of early brain metastases. Theranostics. 2018;8:292-303.
Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry-standardization of nomenclature. J Nucl Med. 2009;50:477-484.
Šefl M, Pachnerová Brabcová K, Štěpán V. Dosimetry as a catch in radiobiology experiments. Radiat Res. 2018;190:404-411.
Huang C-Y, Guatelli S, Oborn BM, Allen BJ. Microdosimetry for targeted alpha therapy of cancer. Comput Math Methods Med. 2012;2012:153212.
Sgouros G, Roeske JC, McDevitt MR, et al. MIRD Pamphlet No. 22 (Abridged): radiobiology and dosimetry of α-particle emitters for targeted radionuclide therapy. J Nucl Med. 2010;51:311-328.
Cheng VW, Soto MS, Khrapitchev AA, et al. VCAM-1 targeted magnetic resonance imaging enables detection of brain micrometastases from different primary tumours. Clin Cancer Res. 2018; 25:533-543.
Soto MS, Serres S, Anthony DC, Sibson NR. Functional role of endothelial adhesion molecules in the early stages of brain metastasis. Neuro Oncol. 2014;16:540-551.
Serres S, Soto MS, Hamilton A, et al. Molecular MRI enables early and sensitive detection of brain metastases. Proc Natl Acad Sci USA. 2012;109:6674-6679.
Boudousq V, Bobyk L, Busson M, et al. Comparison between internalizing Anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb. PLoS ONE. 2013;8:1-12.
Tan Z, Chen P, Schneider N, et al. Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice. Int J Oncol. 2012;40:1881-1888.
Ackerman NL, de la Fuente Rosales L, Falzone N, Vallis KA, Bernal MA. Targeted alpha therapy with 212Pb or 225Ac: change in RBE from daughter migration. Phys Med. 2018;51:91-98.
Sarrut D, Bardiès M, Boussion N, et al. A review of the use and potential of the GATE Monte Carlo code for radiation therapy and dosimetry applications. Med Phys. 2014;41:064301.
Schneider CA, Rasband WS, Eliceiri KW. NIH image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671-675.
Rahmanian S, Niklas M, Abdollahi A, Jäkel O, Greilich S. Application of fluorescent nuclear track detectors for cellular dosimetry. Phys Med Biol. 2017;62:2719-2740.
Sadremomtaz A, Masoumi M. Cellular dosimetry of different radionuclides for targeted radionuclide therapy: Monte Carlo simulation. Biomed Phys Eng Express. 2018;4:065006.